At the forefront of digestive and liver health, our Gastroenterology and Hepatology Research Team is dedicated to advancing clinical knowledge and improving patient outcomes through cutting-edge research.
Based at the Royal Liverpool University Hospital, our multidisciplinary team of clinicians and research nurses work closely together to investigate some of the most pressing challenges in digestive and liver disease.
Our Research Team collaborates strictly with many pharmaceutical and biotechnology companies across the world and with the most important Universities in the UK with the goal of improving patient outcomes and quality of life.
Why Participate?
Many of our studies are currently open for patient enrolment. By participating in a clinical trial, you contribute to vital medical discoveries and may benefit from access to the latest diagnostic tools and treatments under expert care.
Get in touch with our Team
If you are interested in taking part in any of the research studies listed above, please get in touch with us.
Email address: gastro_hepatologyresearch@liverpoolft.nhs.uk
Current research
Oesophageal cancer
This study aims at developing a non-invasive breath test for early detection of oesophageal cancer. The goal is to diagnose oesophageal cancer earlier, increasing treatment options and improving survival rates.
More info about this study can be found here: ViSON
>AROMA 1: This study aims at constructing a cancer detection model based on the augmented breath test, and to refine the baseline breath test.
More info can be found here: AROMA
Inflammatory Bowel Disease (IBD)
A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Crohn's Disease.
For more info please click here: SIBERITE
An observational study on perianal and fistulating Crohn’s disease. The primary objective is to provide data on diagnosis, treatment and outcomes in this population.
For more info please click here: GONDOMAR
A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Ulcerative Colitis.
For more info please click here: AMETRINE
The IBD BioResource aims to support studies looking at how genes and environmental factors influence IBD and response to therapy.
For more info please click on the following here: IBD BioResource
The aim of this study is to validate a predictive model for clinical response of failure to respond to biologic, JAKi or S1PR modulating therapies in IBD and to determine the relationship between clinical response and remission to a specific advanced therapy agent.
For more info please click here: IBD-RESPONSE
This Phase 2 study is testing rosnilimab in people with moderate to severe ulcerative colitis.
Surgical studies
The primary aim of this trial is to determine whether pre-operative Exclusive Enteral Nutrition (EEN) is more clinically and cost effective compared with usual diet in patients undergoing surgery for Crohn’s disease (CD).
For more info please click here: OCEaN
The aim of this study is to describe the differences in practice regarding surgical intervention in Ulcerative Colitis (UC) across European countries, to document the morbidity rates for all UC interventions, to document the physical history of surgery for UC in large volumes and to identify potential differences that correlate to better outcomes.
This study is testing whether an early procedure, TIPSS, can improve survival in patients with severe bleeding from liver disease, compared to current standard treatments. It will also look at cost and quality of life to find the best overall approach.
Liver studies
A study to evaluate the safety, tolerability and efficacy of RTX001 Autologous Macrophages in participants with liver cirrhosis who have hepatic decompensation.
For more info click here: EMERALD
A study that evaluates the cost-effectiveness of the CirrhoCare digital home monitoring and management system in patients with decompensated cirrhosis.
For more info please click here: CirrhoCare
This Phase 1/2 study tests a new cell therapy, RTX001, for patients with liver cirrhosis after a serious complication.
This trial is looking at aspirin to reduce the risk of cancer, liver disease and the need for a liver transplant in patients affected by primary sclerosing cholangitis and IBD.
For more info please click here: Asp-PSC
The study is looking at the identification of genetic variants associated with primary biliary cholangitis.
For more info click here: UK-PBC
OPERA is a new trial evaluating a novel treatment strategy in newly diagnosed patients with primary biliary cholangitis (PBC).
For more info click here here: OPERA
The study will use a system to randomly assign participants to one of three treatment groups without anyone knowing who gets what. Patients and study staff won’t know the treatment given to keep the trial fair. Randomisation will consider if a patient has type 2 diabetes and their liver fibrosis level.
This trial is testing whether long-term abdominal drains (LTADs) improve quality of life for patients with fluid buildup in the belly from liver scarring (cirrhosis) compared to the usual hospital drainage.
This clinical trial is evaluating the effectiveness of survodutide compared to a placebo in people with liver fibrosis (F2–F3). Participants are randomly assigned in a 2:1 ratio and remain in the study until a set number of key health outcomes are reached.
For more information, please contact our Gastro team.
This study is testing a medicine to see if it can protect the liver in people with alcohol-related liver disease. It aims to mimic a natural genetic protection by reducing a specific liver protein linked to liver damage.
